Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C24H20ClFN4O4 |
| Molecular Weight | 482.891 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(O)C(=O)NC1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1
InChI
InChIKey=NWFMVILQVXZATJ-UHFFFAOYSA-N
InChI=1S/C24H20ClFN4O4/c25-19-10-17(5-7-22(19)34-12-14-2-1-3-15(26)8-14)29-23-18-9-16(30-24(33)21(32)11-31)4-6-20(18)27-13-28-23/h1-10,13,21,31-32H,11-12H2,(H,30,33)(H,27,28,29)
| Molecular Formula | C24H20ClFN4O4 |
| Molecular Weight | 482.891 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:19:55 GMT 2025
by
admin
on
Wed Apr 02 07:19:55 GMT 2025
|
| Record UNII |
GGA6DL772Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1469980-18-4
Created by
admin on Wed Apr 02 07:19:55 GMT 2025 , Edited by admin on Wed Apr 02 07:19:55 GMT 2025
|
PRIMARY | |||
|
156028094
Created by
admin on Wed Apr 02 07:19:55 GMT 2025 , Edited by admin on Wed Apr 02 07:19:55 GMT 2025
|
PRIMARY | |||
|
GGA6DL772Q
Created by
admin on Wed Apr 02 07:19:55 GMT 2025 , Edited by admin on Wed Apr 02 07:19:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET->WEAK INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
FECAL; PLASMA; URINE
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
IN CANCER PATIENTS |
|
||
| Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
| Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
| Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||